NAV

Pimobendan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pimobendan
DrugBank Accession Number
DB11450
Background

Not Available

Type
Small Molecule
Groups
Vet approved
Structure
3D
Similar Structures
Weight
Average: 334.379
Monoisotopic: 334.142975836
Chemical Formula
C19H18N4O2
Synonyms
  • dl-Pimobendan
  • Pimobendan
  • Pimobendane
  • Pimobendanum
External IDs
  • UDCG-115
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Acardi

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylbenzimidazoles. These are compounds containing a phenylbenzimidazole skeleton, which consists of a benzimidazole moiety where its imidazole ring is attached to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Phenylbenzimidazoles
Direct Parent
Phenylbenzimidazoles
Alternative Parents
Phenylimidazoles / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / Pyridazines and derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 1 more
Substituents
2-phenylimidazole / Alkyl aryl ether / Anisole / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Ether / Heteroaromatic compound / Hydrocarbon derivative
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyridazinone, benzimidazoles (CHEBI:32003)
Affected organisms
Not Available

Chemical Identifiers

UNII
34AP3BBP9T
CAS number
74150-27-9
InChI Key
GLBJJMFZWDBELO-UHFFFAOYSA-N
InChI
InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
IUPAC Name
6-[2-(4-methoxyphenyl)-1H-1,3-benzodiazol-5-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one
SMILES
COC1=CC=C(C=C1)C1=NC2=CC(=CC=C2N1)C1=NNC(=O)CC1C

References

General References
  1. Galatulas I, Bossa R, Efstathiu G, Ninci MA: Esorubicin cardiotoxicity in vitro: antagonism by pimobendan. Acta Physiol Hung. 1990;75 Suppl:123-4. [Article]
  2. Hanzlicek AS, Gehring R, Kukanich B, Kukanich KS, Borgarelli M, Smee N, Olson EE, Margiocco M: Pharmacokinetics of oral pimobendan in healthy cats. J Vet Cardiol. 2012 Dec;14(4):489-96. doi: 10.1016/j.jvc.2012.06.002. Epub 2012 Oct 30. [Article]
  3. Fujino K, Sperelakis N, Solaro RJ: Direct effects of pimobendan on cardiac myofilaments. Prog Clin Biol Res. 1989;315:602-3. [Article]
  4. Peters P, Saborowski F, Kothe A: [Effect of pimobendan on peripheral hemodynamics]. Z Kardiol. 1989 Aug;78(8):538-44. [Article]
  5. van Meel JC, Mauz AB, Wienen W, Diederen W: Pimobendan increases survival of cardiomyopathic hamsters. J Cardiovasc Pharmacol. 1989 Mar;13(3):508-9. [Article]
  6. Zvirgzdins A, Delina M, Mishnev A, Actins A: Pimobendan B from powder diffraction data. Acta Crystallogr Sect E Struct Rep Online. 2013 Oct 19;69(Pt 11):o1677. doi: 10.1107/S1600536813028353. eCollection 2013 Nov 1. [Article]
  7. van Meel JC, Diederen W: Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol. 1989;14 Suppl 2:S1-6. [Article]
  8. Tsuda T, Izumi T, Kodama M, Hanawa H, Takahashi M, Suzuki M, Aizaki T, Uchiyama H, Kuwano H, Shibata A: Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan. Jpn Heart J. 1992 Mar;33(2):193-203. [Article]
  9. Scheld HH, Fritsche R, Schlepper M, van Meel JC: Pimobendan increases calcium sensitivity of skinned human papillary muscle fibers. J Clin Pharmacol. 1989 Apr;29(4):360-6. [Article]
KEGG Drug
D01133
ChemSpider
4657
BindingDB
50282617
RxNav
1110783
ChEBI
32003
ChEMBL
CHEMBL24646
Wikipedia
Pimobendan

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
PowderNot applicable1 g/1g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0147 mg/mLALOGPS
logP3.35ALOGPS
logP2.7Chemaxon
logS-4.4ALOGPS
pKa (Strongest Acidic)11.17Chemaxon
pKa (Strongest Basic)4.76Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area79.37 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity104.68 m3·mol-1Chemaxon
Polarizability37.27 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0129000000-900366a58e4d7b7da367
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-9410921090f8bbd665ec
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00lr-0019000000-960ceb8f06b61a7601f3
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0039000000-0ca5f2a61cf24a1e1128
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01po-2195000000-aebf15c757be7a95dc4b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f79-0091000000-47f4899aa52f0f302969
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-01ox-3191000000-2f703c9c50f396c7432c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-178.5196
predicted
DeepCCS 1.0 (2019)
[M+H]+180.87762
predicted
DeepCCS 1.0 (2019)
[M+Na]+187.9957
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 1A2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Curator comments
Data supporting this enzyme action are limited to an in vitro study.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Kuriya Si, Ohmori S, Hino M, Ishii I, Nakamura H, Senda C, Igarashi T, Kiuchi M, Kitada M: Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes. Drug Metab Dispos. 2000 Jan;28(1):73-8. [Article]

Drug created at February 25, 2016 18:51 / Updated at September 28, 2021 21:54